Form 4: Organon Executive Chair Buys 65,400 Shares
Insider Transaction Report
Organon & Co.'s Executive Chair, Carrie Smith Cox, purchased 65,400 shares of common stock indirectly through an IRA at a weighted average price of $7.6721.
Summary
- Carrie Smith Cox, Executive Chair and Director of Organon & Co. (OGN), acquired 65,400 shares of common stock.
- The transaction occurred on November 12, 2025.
- Shares were purchased at a weighted average price of $7.6721, with individual transaction prices ranging from $7.6630 to $7.6899.
- The shares are beneficially owned indirectly through an IRA.
- Following this transaction, Cox beneficially owns a total of 77,869 shares.
Sentiment
Score: 8
Explanation: The purchase of a significant number of shares by a high-ranking executive and director indicates strong insider confidence in the company's current valuation and future prospects.
Positives
- Executive Chair Carrie Smith Cox increased her indirect ownership in Organon & Co. by purchasing 65,400 shares, signaling confidence in the company.
- Insider buying by a high-ranking executive and director is often interpreted as a positive indicator of management's belief in the company's future prospects and valuation.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Procedural Delegation | Carrie Smith Cox executed a Power of Attorney on July 29, 2025, appointing Tarnetta V. Jones and Faye C. Brown as attorneys-in-fact to execute and file SEC Forms 3, 4, and 5 on her behalf and manage her EDGAR account. | 07/29/2025 | Streamlines the process for the executive's SEC compliance filings without altering the company's core governance structure. |
Stakeholder Impact
- Shareholders may view the insider purchase as a positive signal, potentially increasing confidence in the company's stock and future performance.
Key Dates
| Date | Description |
|---|---|
| 07/29/2025 | Carrie Smith Cox executed a Power of Attorney appointing Tarnetta V. Jones and Faye C. Brown as attorneys-in-fact for SEC filings. |
| 11/12/2025 | Date of the reported transaction where 65,400 shares of common stock were purchased. |
| 11/13/2025 | Date the Form 4 was signed by the attorney-in-fact. |
Recommendation
buyThe significant purchase of common stock by Executive Chair Carrie Smith Cox signals strong insider confidence in Organon & Co.'s valuation and future outlook. Such a move by a key executive often precedes positive developments or reflects a belief that the stock is undervalued, making it a potential 'buy' signal for investors.
Keywords
Organon, OGN, insider buying, stock purchase, Carrie Smith Cox, executive, director, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.